https://www.selleckchem.com/products/mdl-800.html
[11%]), and anaemia (four [7%]). A total of 60 serious adverse events occurred in 29 participants, five of which were considered possibly related to durvalumab. Five patients died during the study treatment; none of these five deaths were attributed to study treatment. The combination of durvalumab, cisplatin, and pemetrexed has promising activity and an acceptable safety profile that warrants further investigation in a randomised phase 3 trial. AstraZeneca. AstraZeneca. Venetoclax plus obinutuzumab has been established as a fixed-durat
Like
Comment
Share
